Scarica l'app Stockscreener
3.92
5.95%
0.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.70
Aprire:
$3.78
Volume 24 ore:
2.64M
Relative Volume:
1.87
Capitalizzazione di mercato:
$302.58M
Reddito:
-
Utile/perdita netta:
$-78.15M
Rapporto P/E:
-4.5725
EPS:
-0.8573
Flusso di cassa netto:
$-68.89M
1 W Prestazione:
+9.80%
1M Prestazione:
+9.50%
6M Prestazione:
+149.68%
1 anno Prestazione:
+41.01%
Intervallo 1D:
$3.75
$3.96
Intervallo di 1 settimana:
$3.4101
$3.96
Portata 52W:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Nome
Eledon Pharmaceuticals Inc
Settore
Industria
Telefono
949-238-8090
Indirizzo
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.92 | 302.58M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Guggenheim | Buy |
| 2022-05-13 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Iniziato | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Eledon Pharma To Present At The American Transplant Congress - RTTNews
Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Eledon trial shows all 12 diabetes patients achieve insulin independence By Investing.com - Investing.com Australia
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Midday Stock Roundup: Eledon Up 4% on T1D Trial Results - Orange County Business Journal
Eledon Pharmaceuticals stock surges on diabetes trial results By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals stock surges on diabetes trial results - Investing.com
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegoprubart in T1D Trials - GuruFocus
Eledon trial shows all 12 diabetes patients achieve insulin independence - Investing.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - The Manila Times
12 longtime type 1 diabetes patients stop insulin after islet transplant - Stock Titan
Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote, News & History - Benzinga
Eledon presents updated trial data on tegoprubart for type 1 diabetes at ADA 2026. - Pluang
Eledon trial results to be presented at diabetes conference By Investing.com - Investing.com South Africa
Eledon trial results to be presented at diabetes conference - Investing.com
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
Type 1 diabetes islet transplant brings updated tegoprubart data to ADA - Stock Titan
Eledon Pharmaceuticals, Inc. - MLQ.ai
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Breakthrough in Diabetes Treatment with ELDN's New Drug Submissi - GuruFocus
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND SubmissionEledon Pha - Benzinga
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
ELDN Technical Analysis & Stock Price Forecast - Intellectia AI
Eledon to present kidney transplant trial data at conference - Investing.com UK
Eledon to present kidney transplant trial data at conference By Investing.com - Investing.com Australia
Eledon to present new Phase 2 data on tegoprubart for kidney transplant rejection at June congress - Pluang
New kidney transplant rejection data from tegoprubart at ATC - Stock Titan
Eledon Pharmaceuticals to Present New Long-Term Data from - GlobeNewswire
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
BVF Group Discloses Convertible Stakes in Eledon (ELDN) — 9.99% Blockers - Stock Titan
Eledon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $8.2, Implies 111% Upside - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
How Should Investors Value Eledon Pharmaceuticals (ELDN) After Q - GuruFocus
Eledon (ELDN) Advances in Tegoprubart Development with Key Miles - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Q1 Loss, Cash Reserves Dec - GuruFocus
Eledon Pharma Expects Cash, Cash Equivalents and Short-Term Investments to Fund Ops Into 2Q 2027 >ELDN - Moomoo
Eledon Pharmaceuticals Inc Azioni (ELDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):